Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Moffitt Cancer Center

Sites in Tampa, FL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
709
Shown on this page
12
Current sort
Recently updated
Campus scope
Moffitt Cancer Center, Tampa, FL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Moffitt Cancer Center, Tampa, FL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 157–168 of 709 matching trials with a site at Moffitt Cancer Center, Tampa, FL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

NCT06697184
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
Interventions
Sonrotoclax, Zanubrutinib
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
6
States / cities
Tampa, Florida • Fort Wayne, Indiana • Westwood, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
22
States / cities
Duarte, California • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Understanding and Predicting Breast Cancer Events After Treatment

NCT02791581
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2032
U.S. locations
66
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 1 Interventional

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758
Status at this site: Recruiting
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab, AB248
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 90 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Gilbert, Arizona • Los Angeles, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06801236
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Interventions
ACE-232 tablets
Drug
Lead sponsor
Acerand Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

NCT02923778
Site status not listed — check the official record
View directory record Official record
Conditions
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Talimogene Laherparepvec
Procedure · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
33
States / cities
San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
TAR-210, Gemcitabine, MMC
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
38
States / cities
Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 1 Interventional

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

NCT06234397
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
BH3120, pembrolizumab
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Tampa, Florida • Grand Rapids, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Active, not recruiting No phase listed Observational

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

NCT05687188
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Blood Sample Collection, Tissue Sample Collection, Data Collection, Medical Image Collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Tampa, Florida • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Tampa, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
Erdafitinib Intravesical Delivery System
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:27 PM EDT

About this Moffitt Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Moffitt Cancer Center in Tampa, FL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.